Use

The new Scleroderma Comprehensive Plus Profile is the most comprehensive Scleroderma panel available on the market, and when combined with typical clinical features, can assist in the diagnosis and management of early or established disease. Identifying autoantibodies earlier in the disease can aid in diagnosis, prognosis and predicting the risk for end-stage organ complications, allowing for more aggressive intervention. In Scleroderma patients, anti-PM/Scl-75 and anti-PM/Scl-100 antibodies can be found in diffuse or limited cutaneous disease. The presence of both antibodies is highly associated with inflammatory Myositis.